Literature DB >> 18631215

Antipsychotic drugs increase N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells.

Peethambaran Arun1, Chikkathur N Madhavarao, John R Moffett, Aryan M A Namboodiri.   

Abstract

N-Acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) are related neuronal metabolites associated with the diagnosis and treatment of schizophrenia. NAA is a valuable marker of neuronal viability in magnetic resonance spectroscopy, a technique which has consistently shown NAA levels to be modestly decreased in the brains of schizophrenia patients. However, there are conflicting reports on the changes in brain NAA levels after treatment with antipsychotic drugs, which exert their therapeutic effects in part by blocking dopamine D(2) receptors. NAAG is reported to be an agonist of the metabotropic glutamate 2/3 receptor, which is linked to neurotransmitter release modulation, including glutamate release. Alterations in NAAG metabolism have been implicated in the development of schizophrenia possibly via dysregulation of glutamate neurotransmission. In the present study we have used high performance liquid chromatography to determine the effects of the antipsychotic drugs haloperidol and clozapine on NAA and NAAG levels in SH-SY5Y human neuroblastoma cells, a model system used to test the responses of dopaminergic neurons in vitro. The results indicate that the antipsychotic drugs haloperidol and clozapine increase both NAA and NAAG levels in SH-SY5Y cells in a dose and time dependant manner, providing evidence that NAA and NAAG metabolism in neurons is responsive to antipsychotic drug treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18631215     DOI: 10.1111/j.1471-4159.2008.05524.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Considerations for the Use of SH-SY5Y Neuroblastoma Cells in Neurobiology.

Authors:  Jane Kovalevich; Maryline Santerre; Dianne Langford
Journal:  Methods Mol Biol       Date:  2021

2.  N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia.

Authors:  Frank Jessen; Natascha Fingerhut; Alois M Sprinkart; Kai-Uwe Kühn; Nadine Petrovsky; Wolfgang Maier; Hans-H Schild; Wolfgang Block; Michael Wagner; Frank Träber
Journal:  Schizophr Bull       Date:  2011-09-12       Impact factor: 9.306

3.  Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.

Authors:  Kristen A Rahn; Crystal C Watkins; Jesse Alt; Rana Rais; Marigo Stathis; Inna Grishkan; Ciprian M Crainiceau; Martin G Pomper; Camilo Rojas; Mikhail V Pletnikov; Peter A Calabresi; Jason Brandt; Peter B Barker; Barbara S Slusher; Adam I Kaplin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

4.  Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells.

Authors:  Gabriela Maciel Vieira; Fernanda Crunfli; Caroline Brandão-Teles; Giuliana S Zuccoli; Bradley J Smith
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

5.  Metabolic acetate therapy for the treatment of traumatic brain injury.

Authors:  Peethambaran Arun; Prasanth S Ariyannur; John R Moffett; Guoqiang Xing; Kristen Hamilton; Neil E Grunberg; John A Ives; Aryan M A Namboodiri
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

6.  Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.

Authors:  Daiying Zuo; Tomasz Bzdega; Rafal T Olszewski; John R Moffett; Joseph H Neale
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

7.  Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology.

Authors:  Jane Kovalevich; Dianne Langford
Journal:  Methods Mol Biol       Date:  2013

8.  N-Acetyl and Glutamatergic Neurometabolites in Perisylvian Brain Regions of Methamphetamine Users.

Authors:  Jinsong Tang; Joseph O'Neill; Jeffry R Alger; Zhiwei Shen; Maritza C Johnson; Edythe D London
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

9.  Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson's disease.

Authors:  Alysia Ross; Viktoria Xing; Ting Ting Wang; Samantha C Bureau; Giovana A Link; Teresa Fortin; Hui Zhang; Shawn Hayley; Hongyu Sun
Journal:  Mol Brain       Date:  2020-07-31       Impact factor: 4.041

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.